(CODX) Co-Diagnostics - Ratings and Ratios

Co-Diagnostics, Inc. (NASDAQ:CODX) is a molecular diagnostics company specializing in the development, manufacturing, and distribution of reagents and diagnostic tools for nucleic acid detection. The companys Co-Dx PCR platform enables polymerase chain reaction (PCR) testing in point-of-care and at-home settings, addressing a range of infectious diseases, including COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and zika virus. Additionally, the company offers multiplexed tests for mosquito-borne disease identification, molecular tools for infectious disease detection, liquid biopsy solutions for cancer screening, and agricultural applications such as genetic trait identification in plant and animal genomes. Its portable diagnostic device brings PCR technology to decentralized settings, enhancing accessibility for patients. Founded in 2013, Co-Diagnostics is headquartered in Salt Lake City, Utah.

3-Month Forecast: Based on , CODX is currently trading at $0.56, below its SMA20 ($0.61) and SMA50 ($0.71), indicating bearish momentum. The SMA200 ($1.08) suggests a potential downside target if the stock continues to weaken. The ATR of $0.07 reflects moderate volatility. With an average volume of 85,066 shares over 20 days, liquidity remains limited. From a perspective, the companys market cap of $19.50M, P/B ratio of 0.35, and P/S ratio of 2.66 indicate undervaluation relative to book value but elevated valuation relative to sales. The negative RoE (-64.73%) highlights profitability challenges. Over the next 3 months, CODX may face further price pressure due to bearish technical momentum and weak profitability metrics, with potential support levels emerging near $0.50. Fundamental improvements in earnings or revenue growth could stabilize the stock, but near-term downside risks appear elevated.